Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.
Qian Y, Hua E, Bisht K, Woditschka S, Skordos KW, Liewehr DJ, Steinberg SM, Brogi E, Akram MM, Killian JK, Edelman DC, Pineda M, Scurci S, Degenhardt YY, Laquerre S, Lampkin TA, Meltzer PS, Camphausen K, Steeg PS, Palmieri D. Qian Y, et al. Among authors: degenhardt yy. Clin Exp Metastasis. 2011 Dec;28(8):899-908. doi: 10.1007/s10585-011-9421-9. Epub 2011 Sep 21. Clin Exp Metastasis. 2011. PMID: 21953073 Free PMC article.
Targeting Polo-like kinase in cancer therapy.
Degenhardt Y, Lampkin T. Degenhardt Y, et al. Clin Cancer Res. 2010 Jan 15;16(2):384-9. doi: 10.1158/1078-0432.CCR-09-1380. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068088 Review.
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP. Olmos D, et al. Among authors: degenhardt yy. Clin Cancer Res. 2011 May 15;17(10):3420-30. doi: 10.1158/1078-0432.CCR-10-2946. Epub 2011 Apr 1. Clin Cancer Res. 2011. PMID: 21459796 Clinical Trial.
Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.
Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, Zhang X, Bleam M, Halsey W, Hughes A, Moy C, Liu-Sullivan N, Powers S, Bachman K, Jackson J, Weber B, Wooster R. Degenhardt Y, et al. Mol Cancer Ther. 2010 Jul;9(7):2079-89. doi: 10.1158/1535-7163.MCT-10-0095. Epub 2010 Jun 22. Mol Cancer Ther. 2010. PMID: 20571075
Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y. Jing J, et al. Mol Cancer Ther. 2012 Mar;11(3):720-9. doi: 10.1158/1535-7163.MCT-11-0505. Epub 2011 Dec 14. Mol Cancer Ther. 2012. PMID: 22169769
21 results